ReviewCirculation research2025
Advances in Our Understanding of Cardiovascular Diseases After Preeclampsia.
Review in Circulation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Hypertensive Disorders of Pregnancy and Cardiovascular-Kidney-Metabolic Syndrome.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Association of the Endothelial Activation and Stress Index (EASIX) and the sFlt-1/PlGF Ratio in Patients with Preeclampsia.Diagnostics (Basel, Switzerland) · 2026Article
- 5-Methylcytidine RNA Epitranscriptomics in Women's Health and Disease: Mechanisms and Clinical Implications.Cells · 2026Review
- Comparative maternal-fetal outcomes associated with different antihypertensive treatment strategies in preeclampsia: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Discovery and validation of GNA12Frontiers in neurology · 2026Article
- Inhibitory immune checkpoints in preeclampsia: current landscape, mechanisms, and clinical perspectives.Frontiers in immunology · 2026Review
- Growth differentiation factor 15 (GDF-15) as an emerging biomarker for cardiovascular and kidney diseases, a therapeutic target in cancer and a potential biomarker for preeclampsia.Frontiers in pharmacology · 2026Article
- CRP-triglyceride-glucose index (CTGI) as a predictor of preeclampsia: a population-based study of risk stratification.Lipids in health and disease · 2025Article
- Long-Term Biochemical and Cardiovascular Profiles 3-6 Years After Preeclampsia: Impact of Angiogenic Imbalance During Pregnancy.Journal of clinical medicine · 2025Article
- The Impact of Preeclampsia and Gestational Diabetes on Future Maternal Cardiometabolic Health.Acta physiologica (Oxford, England) · 2025Review
- AT1R autoantibody impedes fetal hepatic glycogen synthesis by inhibiting PI3K/AKT signaling pathway during late gestation.Journal of translational medicine · 2025Article
- The role of sex differences in cardiovascular, metabolic, and immune functions in health and disease: a review for "Sex Differences in Health Awareness Day".Biology of sex differences · 2025Review
- Positive association between fibrinogen-to-albumin ratio and preeclampsia risk in pregnant women of advanced maternal age: implications for clinical risk assessment.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Preeclampsia is a syndrome of hypertension in association with target organ dysfunction, including proteinuria, which manifests during pregnancy and the immediate postpartum period. The pathophysiology of preeclampsia originates from impaired trophoblastic invasion of the placental resulting in malperfusion and involves multiple mechanistic pathways that include anti-angiogenic factors, endothelial dysfunction, and immune dysregulation. Preeclampsia caries an increased risk of subclinical cardiovascular disease including left ventricular remodeling, diastolic dysfunction, coronary artery calcification, peripheral vascular abnormalities, and microvascular dysfunction and clinical cardiovascular disease including stroke, heart failure, myocardial infarction, and death from a cardiovascular cause. This review will highlight several common mechanistic pathways shared between preeclampsia and cardiovascular diseases that provide insight into potential targets for risk reduction and disease process mitigation that can be examined in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.